Sai Life Sciences IPO Allotment Finalized: Strong Demand, GMP Shows Positive Listing Expectations
The allotment for Sai Life Sciences IPO is expected to be finalized today, Monday, December 16, 2024, after the subscription for the ₹3,042.62 crore public offering closed on Friday, December 13, 2024. The IPO saw healthy participation, with an overall oversubscription of 10.26 times.
Once the allotment is concluded, investors can check the status of their shares on the official websites of BSE, NSE, or Kfin Technologies, the registrar for the issue. Direct links for checking the allotment status are as follows:
- BSE: Check allotment status on BSE
- Kfin Technologies: Check allotment status on Kfin
- NSE: Check allotment status on NSE
Sai Life Sciences IPO Final Subscription Status
The ₹3,042.62 crore public offering, with a price band of ₹522-₹549 per share and a lot size of 27 shares, received a significant response from investors. The issue attracted 39.86 crore bids against the 3.88 crore shares on offer, resulting in an oversubscription of 10.26 times, according to NSE data.
The subscription breakdown is as follows:
- Qualified Institutional Buyers (QIBs): Subscribed 30.90 times their reserved quota.
- Non-Institutional Investors (NIIs): Subscribed 4.92 times their share.
- Retail Individual Investors (RIIs): Subscribed 1.37 times the allocated portion.
Grey Market Premium (GMP) and Listing Price Prediction
Shares of Sai Life Sciences are currently trading at a grey market premium (GMP) of ₹61, reflecting an 11.11% premium over the upper end of the IPO price band of ₹549, according to sources tracking the grey market.
The company is scheduled to list its shares on the BSE and NSE on Wednesday, December 18, 2024. If the current grey market trends continue, the shares may list around ₹610, representing an 11% premium above the IPO’s upper price band. However, investors should note that the grey market is unregulated, and GMP figures may fluctuate.
About Sai Life Sciences
Sai Life Sciences is a leading player in customized services for biotech firms and global pharmaceutical companies. The company specializes in the research, development, and manufacturing of small-molecule new chemical entities. This positions Sai Life Sciences as a key partner in the pharmaceutical and biotech industries, with a focus on cutting-edge research and product development.
With a strong investor interest and promising GMP figures, Sai Life Sciences’ IPO seems poised for a positive debut on the exchanges.
